Introduction {#sec1}
============

Cutaneous T-cell lymphoma (CTCL) is a heterogenous lymphoproliferative disorder. Mycosis fungoides is the most common variant; Sézary syndrome (SS) is the leukemic counterpart of mycosis fungoides.[@bib1] Treatment ranges from skin-directed therapies to systemic modalities including interferons, extracorporeal photopheresis (ECP), biological agents, and chemotherapy[@bib2]; the latter are indicated for patients with SS. Transformed SS, characterized by the development of skin tumors consisting of large atypical T cells, represents late-stage disease with a poor prognosis.[@bib3] Here we report a case of transformed SS subsequent to pembrolizumab therapy.

Report of a case {#sec2}
================

An 80-year-old man with SS (stage IVA, T4,N0,M0,B2), diagnosed 8 years ago, presented during pembrolizumab therapy with worsening disease that included new-onset skin tumors and 25-pound weight loss. He previously did not respond to systemic bexarotene, interferon-α, vorinostat, and ECP. Before pembrolizumab therapy, he was erythrodermic without lymph node involvement, and his Sézary cell count was 1251 CD3^+^CD4^+^CD26^-^ cells/μL. Current treatment was monthly ECP, twice-weekly narrow-band ultraviolet B therapy, and monthly pembrolizumab (6 cycles). Physical examination found lymphadenopathy; erythematous, lichenified patches involving 72.5% body surface area (BSA) ([Fig 1](#fig1){ref-type="fig"}); and new, scattered, 0.5- to 2.0-cm, firm, erythematous nodules involving 4.8% BSA ([Fig 2](#fig2){ref-type="fig"}).Fig 1Diffuse erythema involving 72.5% BSA.Fig 2Scattered, 0.5-2.0 cm, firm, pink-purple nodules and tumors.

Positron emission tomography/computed tomography scan after 6 cycles of pembrolizumab found new, hypermetabolic subcutaneous nodules and lymphadenopathy. The patient declined lymph node biopsy. His Sézary cell count had increased to 1779 cells/μL from 1251 cells/μL. Biopsies of 2 patches from the back found psoriasiform hyperplasia and a nonepidermotropic, superficial perivascular infiltrate of small, cerebriform hyperchromatic lymphocytes with a CD2/CD3/CD4/CD5^+^, CD7/CD30^-^ phenotype; 10% had circumferential programmed cell death-1 (PD-1) positivity. The CD4/CD8 ratio was 4. These findings were consistent with erythroderma and a leukemic infiltrate of Sézary lymphocytes. Biopsy of a scalp nodule found a diffuse, deep dermal infiltrate of immunophenotypically identical epidermotropic small cerebriform lymphocytes with admixed eosinophils. A CD4/CD8 ratio of greater than 5 supported a diagnosis of SS with tumors ([Fig 3](#fig3){ref-type="fig"}). Large cell transformation and clonal T-cell receptor rearrangement in the skin were not detected.Fig 3**A-C**, Histopathologic findings before pembrolizumab show psoriasiform hyperplasia with mild spongiosis (**A**), superficial perivascular infiltrate of atypical, cerebriform lymphocytes (**B**), strongly positive for CD4 (**C**), consistent with cutaneous infiltrate of Sézary cells in a background of erythroderma. **D-G**, Histopathologic findings after pembrolizumab of a tumor show nodular and diffuse infiltrate of cerebriform lymphocytes admixed with eosinophils (**D** and **E**), with CD4/CD8 ratio of 5:1 in the dermis and 4-5:1 in the epidermis (**F,G**).

Considering the clinical, laboratory, and histologic evidence of tumor progression, pembrolizumab was discontinued. The patient\'s health continued to deteriorate, and he died 1 year after the initiation of pembrolizumab.

Discussion {#sec3}
==========

Pembrolizumab is a monoclonal antibody that targets the PD-1 receptor on lymphocytes, crippling their ability to activate cytotoxic T cells via the PD-1 ligand.[@bib4] Malignant cells may upregulate expression of PD-1 ligand to evade the host immune response; this phenomenon has been noted in circulating T cells from patients with SS.[@bib4], [@bib5], [@bib6] Pembrolizumab, which is approved by the US Food and Drug Administration for multiple malignancies, binds and blocks the PD-1 receptor on lymphocytes, allowing the host immune response to destroy cancerous cells that would otherwise escape host defenses via inappropriately upregulated PD-1 ligand.[@bib5]^,^[@bib7] Although clinical evidence for its efficacy in CTCL is limited, pembrolizumab was found to provide benefit in other lymphomas; a recent study by Khodadoust et al[@bib8] suggests utility in CTCL.[@bib5]^,^[@bib8] There are currently 8 active clinical trials investigating its use in CTCL; 4 of these include SS.[@bib9]

The most common adverse events with pembrolizumab are cutaneous, including nonspecific rashes and hypopigmentation.[@bib10] These manifestations are thought to be mediated by activation of CD4^+^ and CD8^+^ T cells, although the exact mechanism is poorly understood. There is one case report of a patient who had a form of CTCL during pembrolizumab therapy for metastatic melanoma.[@bib11] Given that pembrolizumab induces proliferation of T cells, it is plausible that some patients with CTCL may suffer progression via this mechanism.[@bib4] Alternatively, pembrolizumab-induced proliferation may magnify the risk of mutations in a population of genetically defective T cells. Although one must consider that this patient\'s progression was merely a manifestation of refractory/progressive disease, continued vigilance for the potential of pembrolizumab to exacerbate T-cell lymphoproliferative disorders seems prudent.
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